On this page
Quick Reference
Overview and Recommendations
Background
- •Understand the pathophysiology as a multi-stage cascade beginning with calcium dysregulation in pancreatic acinar cells. This leads to the premature conversion of trypsinogen to active trypsin, causing cellular autodigestion and the release of damage-associated molecular patterns (DAMPs) that trigger (SIRS).
- •Distinguish between the two clinical phases of the disease: the Early Phase (first week), dominated by the host's systemic inflammatory response and potential early organ failure, and the Late Phase (beyond one week), characterized by local complications such as peripancreatic fluid collections and persistent systemic inflammation.
- •Classify severity using the Revised Atlanta Classification (RAC), which categorizes AP into Mild (no organ failure or complications), Moderately Severe (transient organ failure < 48 hours or local/systemic complications), and Severe (persistent organ failure > 48 hours).
- •Identify the primary etiologies, noting that and biliary sludge account for 40–60% of cases, while alcohol consumption accounts for 20–30%. Metabolic triggers, specifically , become a critical risk when serum levels exceed 1,000 mg/dL (11.3 mmol/L).
- •Recognize the "Enigmatic Triad" of (DKA), hypertriglyceridemia, and acute pancreatitis, where each condition can potentially precipitate the others, complicating the initial diagnostic and metabolic stabilization efforts.
- •Note morphological variants including Interstitial Edematous Pancreatitis (IEP), characterized by diffuse enlargement without necrosis, and Necrotizing Pancreatitis, which involves tissue death of the parenchyma or peripancreatic tissues and carries a higher risk of infection.
Evaluation
- •Suspect acute pancreatitis in any patient presenting with sudden-onset, constant, and severe epigastric pain that often radiates to the back and is described as "boring" or "stabbing." Nausea and vomiting are nearly universal and typically do not relieve the pain.
- •Ask about specific risk factors including alcohol intake, history of symptomatic , recent procedures, and medications such as , , or (gliptins).
- •Examine the patient for signs of SIRS, specifically monitoring for tachycardia (HR > 90 bpm), tachypnea, and fever. Persistent tachycardia over the first 7 days is a strong predictor of mortality and infectious pancreatic necrosis.
- •Perform a thorough abdominal exam to identify guarding or rebound tenderness, which may suggest necrotic collections or an . Look for rare hemorrhagic signs like Cullen’s sign (periumbilical ecchymosis) or Grey Turner’s sign (flank ecchymosis).
- •Order a serum lipase level immediately; a value ≥ 3 times the upper limit of normal is highly suggestive of AP. Note that amylase is less specific and may return to normal more quickly than lipase.
- •Obtain a complete metabolic panel and lipid profile to screen for and assess renal function (creatinine) and liver enzymes (ALT > 150 U/L suggests a biliary etiology).
- •Calculate the Neutrophil-to-Lymphocyte Ratio (NLR) at admission and at 48 hours; a rising or persistently elevated NLR is a low-cost marker for predicting persistent organ failure.
- •Monitor for "Red Flags" indicating the need for ICU escalation, including hypotension unresponsive to initial fluids, altered mental status, or respiratory distress (FVC < 15 mL/kg or rising oxygen requirements).
- •Utilize the Modified Marshall Scoring System to objectively define organ failure across the respiratory (PaO2/FiO2 ratio), renal (serum creatinine), and cardiovascular (systolic blood pressure) systems.
- •Order a contrast-enhanced computed tomography (CECT) scan only if the diagnosis is uncertain or if the patient fails to improve after 48–72 hours, as early imaging may underrepresent the extent of pancreatic necrosis.
- •Screen for on the extensor surfaces of the extremities if hypertriglyceridemic pancreatitis is suspected, and assess for which correlates with worse clinical outcomes.
Management
- •Administer aggressive fluid resuscitation with isotonic crystalloids (Lactated Ringer's is often preferred) at 250–500 mL/h initially, unless cardiovascular or renal contraindications exist. Frequent reassessment of fluid status every 6–12 hours is mandatory to avoid fluid overload.
- •Initiate early enteral nutrition (oral or tube feeding) within 24 hours if tolerated, as it maintains the intestinal barrier and reduces the risk of bacterial translocation and infected necrosis compared to parenteral nutrition.
- •Manage pain aggressively using intravenous opioids (e.g., hydromorphone or fentanyl) or multimodal analgesia; avoid relying solely on NSAIDs in the acute phase due to renal risks.
- •Avoid prophylactic antibiotics in patients with sterile necrosis; antibiotics should be reserved for suspected or confirmed infected necrosis (e.g., new fever, rising WBC, or gas on CT).
- •Administer carbapenems (e.g., Meropenem 1g IV every 8 hours) or quinolones with metronidazole if infected necrosis is confirmed, as these agents have superior pancreatic tissue penetration.
- •Implement the "Step-Up" approach for infected pancreatic necrosis: start with percutaneous or endoscopic ultrasound-guided transluminal drainage (EUS-TD) before considering minimally invasive necrosectomy.
- •Utilize lumen-apposing metal stents (LAMS) for the drainage of walled-off necrosis (WON) to improve drainage efficiency and facilitate early nutritional recovery.
- •Treat severe (TG > 1,000 mg/dL) with an insulin infusion (0.1 units/kg/hour) or plasmapheresis to rapidly lower lipid levels and prevent further acinar injury.
- •Perform a during the same admission for all patients with mild biliary pancreatitis to prevent recurrent attacks; for severe cases, delay surgery until inflammatory collections have stabilized.
- •Monitor Procalcitonin (PCT) levels; a value > 1.0 ng/mL is highly suggestive of pancreatic necrosis and may guide the decision for invasive sampling.
- •Initiate Pancreatic Enzyme Replacement Therapy (PERT) (e.g., Creon 25,000–50,000 units per meal) in patients showing signs of malabsorption or those recovering from necrotizing pancreatitis to manage exocrine insufficiency.
- •Refer patients with persistent organ failure, extensive necrosis, or complex local complications to a tertiary specialized center early (within 24–48 hours) to reduce the risk of progression to SAP.
- •Monitor for pancreatic encephalopathy, characterized by confusion or neurological deficits, which may result from the systemic release of pancreatic enzymes like phospholipase A2.
- •Discharge patients once pain is controlled with oral medications, they can tolerate an oral diet, and systemic inflammatory markers are trending downward. Ensure a follow-up plan for repeat imaging if local collections were present.
Board Review — High Yield
- •Cullen's sign — Periumbilical ecchymosis indicating retroperitoneal hemorrhage/hemorrhagic pancreatitis.
- •Grey Turner's sign — Flank ecchymosis associated with severe necrotizing pancreatitis.
- •Sentinel Loop — A localized ileus of a jejunal loop seen on abdominal X-ray near the inflamed pancreas.
- •Revised Atlanta Classification — Defines severity based on organ failure duration: transient (<48h) vs persistent (>48h).
- •Hypertriglyceridemia — AP risk increases significantly when serum triglycerides exceed 1,000 mg/dL.
- •Step-up approach — The strategy of using percutaneous/endoscopic drainage before surgical necrosectomy for infected necrosis.
- •Pancreatic Encephalopathy — Neurological symptoms caused by circulating pancreatic enzymes and cytokine-mediated neuroinflammation.
- •Iatrogenic triggers — Post-ERCP pancreatitis is a common complication; risk is higher in patients with intrapancreatic fat deposition.
Deep Dive — Evidence Details
Definition, Synonyms, and Classification
- ▸Acute pancreatitis is clinically heterogeneous, ranging from self-limited disease to complicated illness with substantial morbidity and mortality. [106][107]
- ▸The revised Atlanta framework classifies AP as mild, moderately severe, or severe. [106][108]
- ▸Severe AP is defined by persistent organ failure lasting more than 48 hours. [114]
- ▸Post-pancreatectomy acute pancreatitis is a distinct postoperative entity involving symptoms, characteristic CT findings, and sustained postoperative hyperamylasemia for at least 48 hours under the consensus definition. [3][20]
- ▸Biomarkers, scoring systems, imaging models, and phenotypic factors support risk prediction but do not replace outcome-based severity classification. [7][8][9][107][109][110][112][115]
Definition
Acute pancreatitis (AP) is an acute inflammatory disorder of the pancreas with a clinically heterogeneous course, ranging from a self-limited illness to a complication-prone disease associated with substantial morbidity and mortality. Up to approximately one-third of patients may develop complications, supporting classification by clinical severity rather than by symptoms alone. [106] AP is also described as an acute gastrointestinal inflammatory syndrome requiring assessment of both pancreatic injury and systemic consequences. [106][107]
The diagnosis and classification of AP should follow contemporary evidence-based guidance, particularly the revised Atlanta framework, which is used to distinguish mild, moderately severe, and severe disease. [106][108][114] The revised Atlanta classification is clinically outcome-oriented: severe AP is defined by persistent organ failure lasting more than 48 hours, whereas early prediction models attempt to identify patients at risk before this threshold is reached. [114] Non-contrast CT-based artificial-intelligence models have likewise been developed to classify AP as mild, moderately severe, or severe according to the revised Atlanta categories. [108]
Synonyms and related terms
Common synonyms include “acute pancreatitis,” “AP,” and, when persistent organ failure is present, “severe acute pancreatitis” or “SAP.” The term “moderately severe acute pancreatitis” refers to an intermediate category within the revised Atlanta classification, while “mild acute pancreatitis” denotes the least severe category in that framework. [106][108]
“Post-pancreatectomy acute pancreatitis” (PPAP) is a distinct postoperative entity and should not be conflated with ordinary, non-operative AP. The International Study Group for Pancreatic Surgery consensus definition incorporates clinical symptoms, characteristic CT findings, and sustained postoperative hyperamylasemia for at least 48 hours. [3][20]D Studies after distal pancreatectomy have evaluated alternative definitions involving transient postoperative hyperamylasemia lasting less than 48 hours, indicating continuing uncertainty about the most clinically discriminative postoperative criteria. [20]D A systematic review and meta-analysis found that both postoperative hyperamylasemia and PPAP, when defined according to the international consensus, have clinically relevant associations after pancreatectomy. [3]
Classification by severity
| Category | Defining clinical concept | Evidence and qualification |
|---|---|---|
| Mild AP | Mildest revised Atlanta category | Used as a comparator category in contemporary guidelines, imaging models, and observational studies. [106][108] |
| Moderately severe AP | Intermediate revised Atlanta category | Recognized separately from mild and severe disease in current classification and prediction research. [106][108] |
| Severe AP (SAP) | Persistent organ failure for >48 hours | This duration is the reference threshold for the gold-standard classification of severe disease, although it may delay definitive classification. [114] |
| PPAP | Postoperative pancreatitis after pancreatic resection | Requires clinical symptoms, characteristic CT findings, and sustained postoperative hyperamylasemia for ≥48 hours under the consensus definition. [3][20]D |
Severity classification is distinct from risk prediction. Several admission biomarkers and scores—including platelet-to-lymphocyte ratio, neutrophil percentage-to-albumin ratio, neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, BISAP, and APACHE II—are being studied to identify patients likely to develop severe disease, but they do not replace the revised Atlanta outcome-based classification. [7][112][115] Oxidative-stress studies also use differing definitions of AP severity, an inconsistency that must be considered when comparing results across studies. [107] In patients with HIV infection, immune dysregulation may affect the performance of inflammatory biomarkers used to estimate severity, further supporting cautious interpretation of surrogate markers. [109]
Etiologic and phenotypic modifiers
Etiology and patient phenotype are clinically important modifiers but are not substitutes for severity classification. Multiple-substance exposure—including combinations of tobacco, alcohol, cannabis, and illicit substances—has been evaluated as a risk factor for AP. [2] Obesity is associated with more severe disease and higher mortality, while sarcopenia and sarcopenic obesity have been investigated in relation to prolonged hospitalization and adverse outcomes. [110][8] Hypertriglyceridemic AP is a recognized etiologic phenotype; studies have assessed triglyceride thresholds and combined early predictors for identifying severe cases, but these parameters do not create a separate universally accepted severity classification. [113][117]
Other proposed prognostic features include admission immune indices, vitamin D status, hyperglycemia, and non-contrast CT findings. [9][19]D[112][114] These findings may refine risk assessment but remain adjunctive to the clinical classification system. Experimental studies of oxidative, neuroimmune, serotonergic, and ferroptosis-related pathways concern mechanisms or potential interventions rather than diagnostic definitions or established clinical categories. [107][111]
Practical terminology
For documentation, the preferred terminology is “acute pancreatitis, mild,” “acute pancreatitis, moderately severe,” or “acute pancreatitis, severe,” with explicit recording of organ failure, local complications, etiology, and—when relevant—postoperative status. [106][108][114] Classification should be reassessed over time because early clinical prediction and later definitive severity assignment are not equivalent: a patient may initially be considered at high risk, whereas severe AP is established by persistent organ failure beyond 48 hours. [114][115]
| Category | Defining clinical concept | Evidence and qualification |\n|---|---|---|\n| Mild AP | Mildest revised Atlanta category | Used in guidelines and contemporary classification studies. [106][108] |\n| Moderately severe AP | Intermediate revised Atlanta category | Distinguished from mild and severe disease in current research. [106][108] |\n| Severe AP | Persistent organ failure for >48 hours | Definitive severity threshold in the revised Atlanta framework. [114] |\n| PPAP | Postoperative pancreatitis after pancreatic resection | Consensus criteria include symptoms, characteristic CT findings, and sustained hyperamylasemia for ≥48 hours. [3][20]D |
Etiology and Triggering Factors
- ▸Hypertriglyceridemia is an increasingly important AP etiology and is associated with a higher risk of early severe progression and systemic complications [170][136].
- ▸Familial chylomicronemia syndrome is a rare inherited cause of extreme HTG and recurrent AP; severe HTG thresholds used in the cited studies include >885 mg/dL and >11.3 mmol/L in DKA-associated disease [172][128][177].
- ▸Secondary triggers of HTG-AP include poorly controlled diabetes, insulin resistance, DKA, asparaginase, and possibly concurrent lipid-emulsion infusions such as propofol and clevidipine [167][171][176][177].
- ▸ERCP performed for biliary disease can cause post-ERCP pancreatitis; visceral adiposity may predict severe PEP [124][129].
- ▸Smoking is associated with evaluation of recurrence risk after first-episode HTG-AP, while obesity, visceral adiposity, and nutritional status may modify severity or outcomes [126][129][150][175].
Overview
The available updated evidence emphasizes hypertriglyceridemia (HTG), biliary disease and endoscopic procedures, metabolic disorders, medication-associated dyslipidemia, inherited lipid disorders, and selected behavioral or nutritional factors as clinically important contexts for acute pancreatitis (AP). Hypertriglyceridemic acute pancreatitis (HTG-AP) is increasingly recognized as a major AP etiology and is associated with a greater risk of early severe progression, systemic complications, and mortality than AP from other causes [170][136]. In China, HTG-AP has been reported as the second leading cause of AP, although the relative contribution of etiologies varies by population [136].
Hypertriglyceridemia and chylomicronemia
Severe HTG is a major precipitant of AP. Familial chylomicronemia syndrome (FCS), a rare autosomal-recessive disorder of triglyceride metabolism, produces extremely high triglyceride concentrations and a very high lifetime risk of recurrent AP [172]. Clinical validation studies distinguish molecularly confirmed FCS from non-FCS severe HTG, while hospital-based screening studies have used triglycerides >885 mg/dL to identify severe HTG and probable FCS [172][128]. FCS should be considered particularly when severe HTG is persistent, recurrent, or disproportionate to common secondary factors [172][128].
Multifactorial chylomicronemia and secondary metabolic disturbances also contribute to HTG-AP. Poorly controlled type 2 diabetes, insulin resistance, dyslipidemia, and pancreatic fat infiltration may coexist with extreme HTG and lipotoxic metabolic dysregulation [176]C. Diabetic ketoacidosis (DKA) can be accompanied by severe HTG; a pediatric series defined severe HTG as triglycerides >11.3 mmol/L and described this complication across children with DKA [177]C. These observations support assessment of glycemic control and ketotic states when AP occurs with marked HTG [176]C[177]C.
Drug-associated HTG is another potential trigger. Asparaginase therapy can cause severe HTG in children receiving treatment for acute lymphoblastic leukemia; one single-center series defined severe asparaginase-associated HTG as triglycerides >1,000 mg/dL and reported an incidence of 2% among treated patients [167]C. Propofol and clevidipine are both administered as lipid emulsions, and concurrent infusions have therefore been investigated as a possible setting for HTG and AP [171]C. The available multicenter retrospective evidence evaluates the frequency of triglycerides >400 mg/dL and AP during concurrent administration, but does not establish that coadministration independently causes pancreatitis in every exposed patient [171]C.
Biliary disease and procedure-related pancreatitis
Biliary pathology remains an important clinical context for AP. Recent evidence concerns patients undergoing ERCP for choledocholithiasis, including those awaiting cholecystectomy after bile-duct stone extraction [124]. ERCP itself may trigger post-ERCP pancreatitis (PEP), a procedure-related form of AP [129]. Visceral adipose tissue has been studied as an independent predictor of severe PEP in a multicenter retrospective cohort, indicating that body composition may modify the severity of procedure-related pancreatic injury [129]. The evidence on prophylactic biliary stenting after complete stone extraction addresses recurrent choledocholithiasis and subsequent management rather than proving stent placement to be an AP cause [124].
Obesity, adiposity, and metabolic susceptibility
Obesity and excess visceral adiposity may increase susceptibility to severe AP or severe procedure-related disease. A multicenter analysis identified visceral adipose tissue as an independent predictor of severe PEP [129]. Separately, a large propensity-matched analysis examined adults with AP who had undergone bariatric surgery at least 1 year previously; the study was motivated by evidence that obesity is associated with more severe AP and that bariatric surgery may improve metabolic comorbidity and systemic inflammatory burden [175]. Bariatric surgery should therefore be viewed as a modifier of metabolic risk and outcomes, not as an established direct cause of AP [175].
Nutritional and metabolic status may also influence the clinical expression of AP. A retrospective study of 1,600 patients evaluated nutritional status, metabolic and inflammatory biomarkers, dietary patterns, gut-barrier markers, and early versus delayed enteral nutrition; these factors were examined as potential determinants of severity rather than as confirmed primary etiologies [150].
Smoking and recurrence after HTG-AP
Current smoking is a potentially important behavioral factor after an initial HTG-AP episode. A multicenter cohort specifically evaluated baseline current smoking and time-varying recurrence risk after a first episode of HTG-AP, including recurrence timing and recurrence burden [126]. This evidence concerns recurrence rather than initial causation; smoking status should nevertheless be documented during etiologic assessment and secondary-prevention planning [126].
Practical etiologic assessment
In AP accompanied by marked HTG, clinicians should investigate FCS or multifactorial chylomicronemia, diabetes or DKA, insulin resistance, relevant medications, and prior episodes [172][128][176]C[177]C. In patients with recent ERCP or biliary intervention, PEP and residual or recurrent choledocholithiasis should be considered [124][129]. Medication exposure should include asparaginase and lipid-emulsion infusions such as propofol, with attention to measured triglyceride concentrations and the temporal relationship between exposure and AP [167]C[171]C. Current smoking, obesity, visceral adiposity, and nutritional status are relevant modifiers of recurrence or severity even when they are not sufficient to establish the primary etiology [126][129][150][175].
| Context | Relevant evidence and threshold | Clinical implication |
|---|---|---|
| Severe HTG/FCS | FCS carries a high lifetime risk of AP; severe HTG screening used >885 mg/dL [172][128] | Consider inherited or multifactorial chylomicronemia |
| DKA-associated HTG | Severe HTG defined as >11.3 mmol/L in a pediatric DKA series [177]C | Evaluate ketosis, glycemic control, and triglycerides |
| Asparaginase | Severe HTG defined as >1,000 mg/dL; incidence 2% in one pediatric cohort [167]C | Review chemotherapy exposure |
| Propofol/clevidipine | Concurrent lipid-emulsion infusions studied for TG >400 mg/dL and AP [171]C | Review infusion duration and triglyceride monitoring |
| Biliary disease/ERCP | ERCP for choledocholithiasis can be followed by PEP [124][129] | Consider biliary obstruction, residual stones, and PEP |
| Smoking and adiposity | Smoking studied for HTG-AP recurrence; visceral adiposity predicts severe PEP [126][129] | Address modifiable recurrence and severity factors |
Pathophysiology
- ▸AP severity reflects the transition from localized pancreatic inflammation to SIRS and persistent organ dysfunction, with cytokine amplification central to progression. [178][182]
- ▸Hypertriglyceridemia, insulin resistance, alcohol-related hepatitis, malnutrition, and sarcopenia may increase the risk of severe systemic disease. [148][149][150][170][183]
- ▸Gut dysbiosis and intestinal-barrier failure are increasingly implicated; experimental evidence links barrier injury to NLRP3-inflammasome pyroptosis. [140][147]
- ▸Admission fever and composite inflammatory or immune-nutrition indices are prognostic associations, not established causal mechanisms. [112][127][141][144][153]
- ▸Hemoperfusion followed by sequential hemodiafiltration has been studied as an adjunct for severe AP within **72 hours**, but retrospective evidence cannot establish treatment causality. [178]
Initiating pancreatic injury
Acute pancreatitis (AP) begins with pancreatic acinar-cell injury and an inflammatory response that may remain localized or progress to systemic inflammatory response syndrome (SIRS), persistent organ failure, and multiorgan dysfunction. [178][182] The available updated evidence supports a model in which the intensity and duration of inflammation, rather than pancreatic injury alone, largely determine clinical severity. [178][182]
Etiologic and metabolic factors influence this trajectory. Hypertriglyceridemic pancreatitis is associated with early severe progression, systemic complications, and mortality, and lipidomic analyses suggest that disordered lipid metabolism contributes to its biology. [170] In hyperlipidemic AP, the C-reactive-protein–triglyceride–glucose index integrates inflammation and insulin resistance, two potentially interacting pathogenic processes. [149] Alcohol-related pancreatic injury may be amplified when alcohol-related hepatitis is present, because simultaneous hepatic and pancreatic injury can increase systemic inflammation and organ dysfunction. [183] Biliary disease remains clinically relevant because common-bile-duct stones and acute cholangitis may coexist with pancreatic inflammation; evidence concerning operative treatment is stratified by cholangitis severity, although the cited study primarily addresses procedural safety rather than AP mechanisms. [180]
Obesity is characterized by excess adiposity and persistent low-grade systemic inflammation, providing a metabolic background that may modify inflammatory disease, although the cited semaglutide meta-analysis does not establish a direct mechanism for AP. [142] Nutritional status, metabolic stress, and physiological reserve also appear to influence progression; sarcopenia quantified by the psoas muscle index was evaluated as a predictor of progression to moderately severe or severe AP. [148] Nutritional modulation may affect inflammatory signaling, gut-barrier function, organ failure, and mortality, and early enteral nutrition was specifically compared with delayed nutrition using a ≤48-hour timing threshold in a large retrospective cohort. [150]
Immune amplification and systemic inflammation
Pancreatic injury rapidly activates innate immune pathways and recruits inflammatory cells. [182] Circulating pro-inflammatory mediators—including interleukin (IL)-1α, IL-1β, IL-6, and tumor necrosis factor—can amplify local inflammation and contribute to systemic complications, whereas IL-10 and other anti-inflammatory mediators modulate the response. [182] In a multiplex cytokine study, patients with AP had increased IL-1α, IL-1β, IL-6, IL-10, IL-2Rα, interferon-γ, IL-1Rα, IL-16, IL-2, macrophage migration inhibitory factor, interferon-α, IL-5, IL-4, and IL-3 compared with healthy controls, supporting a multidimensional rather than exclusively pro-inflammatory cytokine response. [182]
The clinical expression of this inflammatory state includes fever, leukocyte activation, lymphocyte depletion, hypoalbuminemia, and impaired renal function. [141][112][127][144] Fever on admission was associated in a systematic review and meta-analysis with greater disease severity and mortality, although admission temperature is a prognostic correlate rather than proof that fever causes organ injury. [141] In retrospective studies, admission neutrophil-to-albumin ratio, neutrophil-to-lymphocyte ratio, neutrophil–creatinine index, and global immune-nutrition-inflammation index were investigated as composite indicators of systemic inflammation, nutritional reserve, and early organ dysfunction. [112][127][144][153] Liver injury is a frequent systemic complication; in one cohort, acute liver injury occurred in 37.7% of patients and was associated with systemic inflammatory burden measured by the neutrophil-to-lymphocyte ratio. [127]
Gut barrier dysfunction and microbiota
The intestine is an important secondary target in AP. Gut dysbiosis has been increasingly linked to pancreatic inflammation, intestinal-barrier dysfunction, and disease progression, although the cited bibliometric analysis describes the research landscape rather than proving causality. [140] Experimental evidence indicates that AP can disrupt epithelial tight junctions and promote intestinal barrier failure through NLRP3-inflammasome-related pyroptosis. [147] In murine and cellular models, small extracellular vesicle preparations from healthy individuals reduced AP-associated intestinal injury, restored tight-junction integrity, and acted through a miR-579-3p/ANXA3 pathway that inhibited NLRP3-associated pyroptosis; these findings remain preclinical. [147]
Barrier disruption may facilitate movement of microbial products and amplify systemic inflammation, but the cited clinical and bibliometric evidence does not establish a single microorganism or a uniform microbiota signature as the cause of severe AP. [140][147]
Organ dysfunction and progression to severe disease
When inflammatory signaling becomes systemic, endothelial, pulmonary, renal, hepatic, and other organ systems may be affected, producing SIRS and multiorgan dysfunction. [178][183][184]C Severe AP has no established targeted pharmacological intervention in the cited study; hemoperfusion followed by sequential hemodiafiltration was evaluated as an adjunct to standard medical therapy in patients treated within 72 hours of presentation. [178] Both treatment groups showed improvement in inflammatory markers, and the retrospective propensity-matched comparison assessed organ dysfunction, complications, length of stay, and 28-day mortality, but its observational design limits causal inference. [178]
Systemic severity may be influenced by lipid toxicity, insulin resistance, hepatic comorbidity, nutritional depletion, and reduced muscle reserve. [149][148][150][183] A rare case illustrates the potential complexity of severe metabolic inflammation: concurrent diabetic ketoacidosis and severe AP was followed by sepsis, pneumonia, multiple organ dysfunction, Guillain–Barré syndrome, and Wernicke encephalopathy, although a single case cannot define usual pathophysiology. [184]C
Context-dependent and unresolved mechanisms
AP may occur in special inflammatory or infectious contexts. Idiopathic AP was reported in children with inflammatory bowel disease after exclusion of drug-induced, metabolic, infectious, genetic, and structural causes, indicating that some cases remain mechanistically unexplained even after systematic evaluation. [181]C AP has also been temporally associated with COVID-19 pneumonia in a complex patient with malignancy and chronic pulmonary disease; the report demonstrates temporal association, not viral causation. [151]C
Immune profiling may help distinguish acute from chronic pancreatic disease. In children, TRANCE, TWEAK, FLT-1, HGF, and TRAIL were higher in chronic pancreatitis than in AP or healthy controls, suggesting that persistent immune remodeling differs from the acute inflammatory response. [179] Overall, current evidence supports AP as a dynamic interaction among pancreatic injury, innate immune amplification, metabolic stress, gut-barrier failure, nutritional reserve, and evolving organ dysfunction, while many molecular links remain associative or preclinical. [140][147][170][178][182]
| Domain | Evidence and clinical expression |
|---|---|
| Pancreatic and metabolic injury | Hypertriglyceridemia, lipidomic abnormalities, insulin resistance, alcohol-related injury, and biliary disease may shape severity. [149][170][180][183] |
| Immune activation | IL-1α, IL-1β, IL-6, TNF-related signaling, IL-10, and multiple additional cytokines support a mixed inflammatory and regulatory response. [182] |
| Gut–pancreas axis | Dysbiosis and epithelial-barrier disruption are linked to progression; experimental protection involved miR-579-3p/ANXA3 and NLRP3-pyroptosis inhibition. [140][147] |
| Host reserve and nutrition | Sarcopenia, albumin-related indices, nutritional status, and timing of enteral nutrition may influence progression and outcomes. [112][148][150][153] |
| Systemic organ injury | SIRS may progress to hepatic, renal, respiratory, and multiorgan dysfunction; acute liver injury occurred in 37.7% in one cohort. [127][178][183][184]C |
History and Physical Examination
- ▸Pain is often the presenting symptom of acute pancreatitis and has prognostic significance; document severity, trajectory, functional effect, and response to analgesia. [156]
- ▸Pain intensity may not reflect structural pancreatic injury, particularly in recurrent acute or chronic pancreatitis. [161]
- ▸A recent ERCP or pancreaticobiliary intervention should be specifically elicited because postprocedural pancreatitis is a recognized ERCP adverse event. [72]
- ▸Do not diagnose acute pancreatitis from an isolated enzyme elevation: hyperamylasaemia occurred in 18.6% of children with inflammatory bowel disease in one cohort. [160]
- ▸Assess age, frailty, nutritional status, sarcopenia, pregnancy, mobility, and baseline organ function because these modify vulnerability and recovery. [168,186,187]
Presenting symptoms and pain history
Pain is frequently the presenting symptom of acute pancreatitis (AP) and has prognostic significance; inadequately treated pain may adversely affect outcomes. [156] The initial history should therefore document pain onset, progression, severity, functional impact, previous analgesic use, response to treatment, and associated symptoms. [156] Pain intensity should not be interpreted as a direct measure of structural pancreatic injury, because clinical pain and pancreatic structural changes may correlate poorly, particularly in patients with recurrent acute or chronic pancreatitis. [161]C A history of recurrent attacks, persistent pain between episodes, or features suggesting altered pain processing should be recorded because recurrent acute pancreatitis and chronic pancreatitis may be associated with peripheral and central sensitization. [161]C
Pain assessment should be repeated during the admission rather than limited to the initial encounter. [156] In hospitalized patients, higher serum lipase concentrations have been associated with greater likelihood of receiving analgesics, although this retrospective association should not be treated as a validated substitute for direct pain assessment. [162] Analgesic requirements, failure of initial treatment, and evolving pain should prompt reassessment for complications or an alternative diagnosis. [156]
Etiologic and risk-factor history
The history should seek potential causes and precipitants, including prior pancreatitis, biliary disease or procedures, metabolic disorders, medication exposures, and relevant systemic illness. [156] Recent endoscopic retrograde cholangiopancreatography (ERCP) or other pancreaticobiliary intervention is particularly important because postprocedural pancreatitis is a recognized adverse event associated with ERCP. [72] A history of malignant distal biliary obstruction and recent biliary drainage should also be documented when relevant. [72]
Medication and treatment history should include drugs associated with metabolic disturbances or pancreatic injury, together with recent chemotherapy or biologic exposure. [156] Asparaginase-treated children may develop severe hypertriglyceridemia, defined in one pediatric cohort as a triglyceride concentration of >1,000 mg/dL; most affected patients were asymptomatic, so treatment history and laboratory review may be important even when symptoms are limited. [167]C Hyperamylasaemia may occur in pediatric inflammatory bowel disease and was identified in 18.6% of children in one cohort, emphasizing that an elevated amylase value alone does not establish AP. [160]C
The history should include alcohol exposure, gallstone-related symptoms, hypertriglyceridemia, hypercalcemia, autoimmune disease, trauma, family history, and genetic or structural pancreatic disease when clinically appropriate. [156] In children, the assessment should be adapted to recognized pediatric etiologies and should distinguish a first episode from acute recurrent pancreatitis. [185]
Comorbidities and vulnerability
Baseline comorbidity, frailty, age, nutritional status, and functional capacity should be documented at presentation. [168] In a cohort of 1,034 adults, age was evaluated alongside baseline vulnerability, acute organ dysfunction, and local complications because these factors contribute to heterogeneous short-term outcomes in AP. [168] Older or physiologically vulnerable patients may therefore require particularly careful assessment of mental status, mobility, respiratory effort, urine output, and ability to maintain oral intake. [168]
Nutritional and functional history should include recent weight loss, reduced intake, pre-existing sarcopenia, loss of independence, and exercise tolerance. [186] Moderately severe and severe AP can be accompanied by malnutrition and short-term deterioration in body composition; body composition and sarcopenia were assessed at admission and again after 8 weeks in a prospective observational study. [186] A baseline handgrip-strength or functional assessment may help identify probable sarcopenia when clinically feasible. [186]
Pregnancy status should be established in patients who could be pregnant. [187] AP during pregnancy may adversely affect maternal and fetal outcomes, and severity should be assessed promptly in parallel with gestational and obstetric history. [187]
Physical examination
The examination should begin with a structured assessment of general appearance, pain-related distress, vital signs, mental status, hydration, and perfusion. [156] Particular attention should be paid to respiratory effort and oxygenation, cardiovascular stability, temperature, urine output, and evidence of evolving organ dysfunction because AP severity is linked to systemic complications and organ failure. [168] Abdominal examination should assess tenderness, guarding, rigidity, distension, bowel-sound abnormalities, palpable masses, and evidence of peritoneal irritation; serial examinations are important when pain or systemic findings change. [156]
Examine for jaundice and other evidence of biliary obstruction, as well as signs of dehydration, sepsis, bleeding, or shock. [72] The skin and sclera should be inspected for jaundice, while the extremities should be assessed for perfusion, edema, and functional weakness. [168] In children, document weight, hydration, activity, feeding tolerance, and age-appropriate abdominal findings because pediatric AP may present across a spectrum from limited symptoms to severe disease. [74][185]
Reassessment and diagnostic caution
History and examination should be integrated with laboratory and imaging data rather than relying on pain severity or an isolated enzyme abnormality. [156][160]C[162] A markedly elevated lipase may identify patients more likely to require analgesia, but it does not replace clinical assessment. [162] Similarly, hyperamylasaemia may accompany pediatric inflammatory bowel disease without necessarily representing AP. [160]C Worsening pain, new organ dysfunction, persistent inability to tolerate intake, progressive abdominal findings, or increasing analgesic requirement should trigger repeat clinical evaluation and consideration of complications. [156][168]
In patients with severe AP, prolonged immobility may lead to substantial physical deconditioning; therefore, mobility, independence, and rehabilitation needs should be recorded from admission and reassessed during recovery. [139] A structured early rehabilitation program in intensive-care patients with severe AP was specifically evaluated for effects on functional recovery, length of stay, and survival, supporting inclusion of functional status in the clinical assessment. [139]
| Domain | Findings to document |
|---|---|
| Pain | Onset, progression, severity, functional impact, analgesic use, response, and recurrent or persistent pain. [156][161]C |
| Etiology and exposure | Prior AP, biliary disease, ERCP, metabolic disorders, medications, chemotherapy, alcohol, trauma, and family history. [72][156][167]C |
| Systemic severity | Mental status, perfusion, hydration, respiratory effort, oxygenation, urine output, and evolving organ dysfunction. [156][168] |
| Nutrition and function | Recent intake and weight change, frailty, handgrip or mobility, independence, and sarcopenia risk. [139][186] |
| Special populations | Pregnancy status, pediatric feeding and activity, inflammatory bowel disease, and asparaginase exposure. [74][160]C[167]C[187] |
Supportive Care and Complication Management
- ▸Use individualized, reassessment-guided crystalloid resuscitation; current comparative evidence shows no overall mortality difference between lactated Ringer’s solution and normal saline [193][203].
- ▸Prioritize feasible enteral nutrition, with observational evidence specifically examining initiation within 48 hours [150].
- ▸For hypertriglyceridemic pancreatitis, interpret triglyceride targets and low-molecular-weight heparin effects in the context of disease subphenotype; evidence does not establish universal benefit from a single strategy [113][194].
- ▸Manage symptomatic or infected WOPN through multidisciplinary, anatomy- and clinical-status-guided care using contemporary SAGES/AHPBA-informed recommendations [191].
- ▸Obtain drainage-fluid microbiology when intervening; metagenomic sequencing detected more positives than conventional culture in one prospective study [195].
- ▸Individualize anticoagulation for pancreatitis-associated splanchnic thrombosis because portomesenteric disease and bleeding interventions were both common in the cited cohort [199].
Initial supportive care and fluid resuscitation
Supportive management should be individualized according to disease severity, organ dysfunction, fluid balance, abdominal pressure, renal function, and cardiopulmonary reserve. Early intravenous crystalloid therapy remains central, but the optimal fluid type, rate, and volume are unresolved in observational evidence [193][203]. A 2026 systematic review comparing lactated Ringer’s solution (LR) with normal saline (NS) found no difference in overall mortality between fluids (OR 1.020; 95% CI and additional outcomes were reported in the study) [193]. Thus, fluid choice should be guided by acid–base status, electrolyte abnormalities, renal and cardiac comorbidity, and repeated clinical reassessment rather than by an assumed mortality advantage of either crystalloid [193][203].
Early fluid exposure and its relationship to systemic complications were evaluated in a five-year retrospective study that classified patients as mild or non-mild using Atlanta criteria; the study specifically examined fluid dose within the first 24 hours, complications, and clinical prognosis [203]. Automated CT volumetry of peripancreatic collections has also been investigated as an early risk-stratification tool in a multicenter retrospective cohort, but its role remains prognostic and does not replace bedside assessment [198].
Nutrition and metabolic management
Nutritional status, metabolic stress, inflammatory signaling, and gut-barrier dysfunction may influence outcomes in acute pancreatitis [150]. A retrospective study of 1,600 patients compared enteral nutrition initiated within 48 hours with delayed enteral nutrition and evaluated organ failure, mortality, biomarkers, and nutritional predictors after adjustment for demographic and clinical factors [150]. These data support prioritizing an enteral strategy when clinically feasible, while recognizing that the cited study is observational [150].
Hypertriglyceridemic acute pancreatitis requires attention to triglyceride reduction and the underlying metabolic phenotype. In a retrospective cohort of 345 patients, early achievement of triglycerides ≤5.65 mmol/L within 72 hours was assessed against necrosis, hospital outcomes, and disease severity; no significant difference was observed between goal-achieved and non-goal-achieved groups for the reported pancreatic-necrosis and hospital-outcome comparisons [113]. A separate cohort of 1,483 patients identified hypertriglyceridemic pancreatitis subphenotypes and examined differential responses to low-molecular-weight heparin in an independent randomized trial of 533 patients, indicating that treatment effects may vary across clinically distinct subgroups [194]. Xuesaitong injection has been studied as an off-label adjunct to conventional therapy in randomized trials, but the cited systematic review was designed to determine efficacy and safety and does not establish routine use outside appropriate regional and regulatory contexts [192].
Infected necrosis and walled-off pancreatic necrosis
The 2026 SAGES clinical practice guideline used a systematic review of studies published from 1 January 2020 to 24 January 2025, multidisciplinary input from surgeons, gastroenterologists, and interventional radiologists, and GRADE methodology to address four management questions for symptomatic walled-off pancreatic necrosis (WOPN) in adults [191]. Management should therefore be multidisciplinary and based on symptoms, infection, obstruction, clinical deterioration, anatomy, and procedural feasibility [191].
Microbiology may change with disease timing. In a prospective study of 20 patients undergoing first percutaneous catheter drainage for suspected infected pancreatic necrosis, metagenomic sequencing was positive in 9/20 (45.0%), whereas conventional culture was positive in 6/20 (30.0%); results were compared for drainage performed at ≤14 days versus >14 days after disease onset [195]. These findings support obtaining drainage specimens when intervention is undertaken and interpreting negative cultures in the context of timing and test sensitivity [195]. A retrospective model in 286 patients with hyperlipidemic pancreatitis, externally time-validated in 62 additional patients, evaluated peak D-dimer within 24 hours as a predictor of infected necrosis [196]. D-dimer-based prediction remains investigational and should not replace clinical, laboratory, and imaging assessment [196].
After failed conservative therapy and percutaneous drainage, robot-assisted, conventional minimally invasive, and open necrosectomy were compared retrospectively in 107 patients with infected necrosis. The robot-assisted group included 26 patients, conventional minimally invasive surgery 47, and open surgery 34; robot-assisted procedures had longer operative times than conventional minimally invasive surgery in the reported comparison [197]. A 41-patient case series described perioperative nursing protocols for video-assisted retroperitoneal debridement, but uncontrolled case-series evidence cannot establish comparative efficacy [200]C.
Vascular, abdominal, and infectious complications
Splanchnic vein thrombosis occurred in 13.8% (73/529) of patients with necrotizing pancreatitis in one retrospective study; thrombosis involved the splenic vein in 47.9% and the portomesenteric system in 52.1% [199]. Anticoagulation was used more often with portomesenteric thrombosis than splenic-vein thrombosis (50% vs 17.1%), while bleeding interventions were also reported in the cohort [199]. Anticoagulation decisions should therefore be individualized according to vessel involved, extension, ischemic risk, bleeding risk, and planned interventions [199]. Rare catastrophic complications include pancreaticoportal fistula, illustrated by a case involving portal thrombosis, peripancreatic collections, cutaneous necrosis, septic shock, and multiorgan failure [206]C.
Severe inflammatory activation includes increased circulating IL-1α, IL-1β, IL-6, IL-10, and other cytokines, but cytokine profiling is not established as routine bedside therapy [182]. A reported case of carbapenem-resistant Acinetobacter baumannii infected necrosis with concurrent Enterococcus faecium bacteremia required salvage sulbactam–durlobactam plus tigecycline, emphasizing the need for culture-directed antimicrobial therapy in highly resistant infections rather than routine empiric use of this regimen [205]C. Mirabilite external dressing combined with abdominal drainage was associated with faster pain relief and return of flatus than either comparator in a small retrospective study, but baseline severity differed and the intervention remains insufficiently validated for routine care [201]. EUS-guided drainage evidence in children derives from a retrospective pediatric series comparing lumen-apposing metal and double-pigtail plastic stents and should not be automatically extrapolated to adults [204]C. The EUS-hepaticogastrostomy literature cited here concerns malignant biliary obstruction, not pancreatitis, and is not directly applicable to routine pancreatitis management [125].
| Clinical issue | Evidence | Practical interpretation |
|---|---|---|
| Crystalloid choice | LR versus NS: no overall mortality difference [193] | Select and titrate fluid according to physiology and comorbidity [193][203] |
| Early nutrition | Early EN defined as initiation within 48 hours in a 1,600-patient observational study [150] | Favor enteral delivery when feasible; acknowledge low-certainty observational evidence [150] |
| Hypertriglyceridemia | TG goal ≤5.65 mmol/L within 72 hours was evaluated; reported comparisons did not show significant differences for necrosis and hospital outcomes [113] | Avoid assuming that a biochemical target alone improves outcomes [113] |
| Drainage microbiology | mNGS positive in 45.0% versus culture 30.0% in 20 patients [195] | Use timing-aware, culture-directed evaluation [195] |
| Splanchnic thrombosis | Present in 13.8% of 529 necrotizing-pancreatitis patients [199] | Balance thrombotic and bleeding risks before anticoagulation [199] |
References
- [1]
Vujasinovic M, Demir IE, Marchegiani G et al.. “International Multidisciplinary Consensus Report on Definitions, Diagnostic Criteria, and Management of Fatty Pancreas: A Joint Statement Endorsed by EPC, APA, EASD, EASL, ESGAR, ESGE, ESP, ESPCG, ESPEN, ESPGHAN, IAP, JPS, KPBA, LAPSG, and UEG.” United European gastroenterology journal (2026). PMID: 41689768 ↗
L1cGUIDELINECited in: Definition, Synonyms, and Classification - [2]
Adeniran EA, Jiang Y, Yadav D et al.. “Multiple substance use and the risk of pancreatitis: a systematic review.” Therapeutic advances in gastroenterology (2025). PMID: 40873658 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [3]
Heo D, Cardoso SA, Cardoso RP et al.. “Clinical implications of postoperative hyperamylasemia and postpancreatectomy acute pancreatitis after pancreatectomy: A systematic review and meta-analysis.” Surgery (2025). PMID: 40435914 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [4]
Kowal MR, Bhatnagar V, Pine J et al.. “Systematic review of peritoneal lavage and dialysis for patients with severe acute pancreatitis.” HPB : the official journal of the International Hepato Pancreato Biliary Association (2025). PMID: 39939210 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [5]
Williamson L, Hao Y, Basnayake C et al.. “Systematic review of treatments for the gastrointestinal manifestations of systemic lupus erythematosus.” Seminars in arthritis and rheumatism (2024). PMID: 39461088 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [6]
Haseef M, Li SCH, Gaitt T et al.. “Hypertriglyceridemia: updates from clinical trials of new agents and real-world registries.” Current opinion in endocrinology, diabetes, and obesity (2026). PMID: 41717773 ↗
L2bTRIAL_NONRANDOMCited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors - [7]
Ibrahim MY, Alhaj MM, Ibrahim AAA et al.. “Association of platelet-lymphocyte ratio with acute pancreatitis severity: systematic review and meta-analysis.” BMC gastroenterology (2025). PMID: 41388444 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [8]
Kuzman M, Joseph N, Nafady R et al.. “Clinical Impact of Sarcopenia and Sarcopenic Obesity in Acute Pancreatitis: A Systematic Review.” ANZ journal of surgery (2026). PMID: 41351308 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification, History and Physical Examination - [9]
Siuka D, Rakuša M, Vodenik A et al.. “Free and Bioavailable Vitamin D Are Correlated with Disease Severity in Acute Pancreatitis: A Single-Center, Prospective Study.” International journal of molecular sciences (2025). PMID: 40565159 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [10]
Yahia Y, Abuodeh J, Chandra P et al.. “Risk Factors for Acute Pancreatitis Following Intragastric Balloon Insertion: A 7-Year Retrospective Cohort Study.” Obesity surgery (2025). PMID: 39806256 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [11]
Blažević N, Trkulja V, Rogić D et al.. “YKL-40 as a risk stratification marker in acute pancreatitis: A prospective study.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2025). PMID: 39638701 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [12]
Guilabert L, Cárdenas-Jaén K, Vaillo-Rocamora A et al.. “Normal saline versus lactated Ringer's solution for acute pancreatitis resuscitation, an open-label multicenter randomized controlled trial: the WATERLAND trial study protocol.” Trials (2024). PMID: 39434191 ↗
L2bTRIAL_NONRANDOMCited in: Definition, Synonyms, and Classification - [13]
Grudzińska E, Gajda M. “Postoperative Acute Pancreatitis After Pancreatic Resections-A Narrative Review and a Diagnostic Algorithm.” Cancers (2025). PMID: 40940873 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [14]
Sato A, Tani A, Mishima Y et al.. “Assessment of two different criteria for post-pancreatectomy acute pancreatitis: a single-center retrospective analysis and literature review.” HPB : the official journal of the International Hepato Pancreato Biliary Association (2025). PMID: 40340215 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [15]
Bouça-Machado T, Araújo Teixeira JP, Rebelo P et al.. “Comparison of acute pancreatitis and acute on chronic pancreatitis: a retrospective cohort study.” European journal of gastroenterology & hepatology (2025). PMID: 39976002 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [16]
Ranjan MK, Neupane P, Maharjan B et al.. “Adverse Events Related to Azathioprine Use in Patients With Inflammatory Bowel Disease: A Real-World Cohort Study.” Gastroenterology research and practice (2026). PMID: 41971243 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [17]
Zhou H, Li W, Yang S et al.. “Prediction of acute pancreatitis severity using NLR, procalcitonin, and CT severity score: A retrospective study.” Medicine (2025). PMID: 40629608 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [18]
Orbelian L, Trembach N, Durleshter V. “The Role of Inflammatory and Hemostatic Markers in the Prediction of Severe Acute Pancreatitis: An Observational Cohort Study.” Recent advances in inflammation & allergy drug discovery (2025). PMID: 39694959 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [19]
Dungan KM, Chinchilli VM, Pichardo-Lowden A et al.. “Hyperglycemia During Acute Pancreatitis and Progression to Early-Onset Diabetes After Recovery: Preliminary Findings From the Diabetes Related to Acute Pancreatitis and Its Mechanisms (DREAM) Study.” Diabetes care (2026). PMID: 41940812 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [20]
Poelsler LH, Bellotti R, Pably D et al.. “Analysis of Different Post-Operative Hyperamylasemia Criteria for Defining Post-Pancreatectomy Acute Pancreatitis After Distal Pancreatectomy-A Retrospective Single-Center Study.” Journal of clinical medicine (2026). PMID: 41827220 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [21]
Emara A, Mansour A, Aboeldahab H et al.. “Efficacy and Safety of Olezarsen in Hypertriglyceridemia: An Updated Meta-Analysis of Randomised Controlled Trials.” Diabetes, obesity & metabolism (2026). PMID: 41943994 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [22]
Elbahloul MA, Gamal A, Maihoub O et al.. “Efficacy and Safety of Apolipoprotein C-III Inhibitors in Hypertriglyceridemia: A Network Meta-Analysis of Randomised Controlled Trials.” Diabetes, obesity & metabolism (2026). PMID: 41917770 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [23]
Rehman A, Rajdeep D, Mohnkern JD et al.. “Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Digestive diseases and sciences (2026). PMID: 41865223 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [24]
Peterson AL, Ashraf AP, Bachman J et al.. “Screening, Diagnosis, and Management of Pediatric Hypertriglyceridemia: A Scientific Statement From the American Heart Association.” Arteriosclerosis, thrombosis, and vascular biology (2026). PMID: 41705332 ↗
L1cGUIDELINECited in: Etiology and Triggering Factors - [25]
Masood A, Qureshi AUH, Khalid Z et al.. “Efficacy and safety of antisense oligonucleotide therapies targeting APoC-III in patients with severe hypertriglyceridemia: a meta-analysis of randomized controlled trials.” Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace (2026). PMID: 41755797 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [26]
Loomba R, de-Madaria E, Afghani E et al.. “Clinical Trial: Plozasiran Prevents Recurrent Pancreatitis in Adults With Very Severe Hypertriglyceridemia-Results of a Post Hoc Analysis of the Phase 3 PALISADE Study.” Alimentary pharmacology & therapeutics (2026). PMID: 41923352 ↗
L2bTRIAL_NONRANDOMCited in: Etiology and Triggering Factors - [27]
Qi S, Wang S, Chen W et al.. “Clinical outcomes of lipid apheresis in hypertriglyceridemia-induced acute pancreatitis: A 10-year triglyceride-stratified retrospective study.” Journal of clinical lipidology (2026). PMID: 41963121 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [28]
Cerbino B, Süffert LC, Monteiro A et al.. “Intrapancreatic Fat Deposition and Risk of Post-ERCP Pancreatitis: A Systematic Review and Meta-analysis.” Pancreas (2026). PMID: 41668341 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors - [29]
Shi B, Feng J, Hu P et al.. “Clinical Outcomes and Safety of Ureteral Catheter-Assisted Antegrade Guidewire Intubation in the Laparoscopic-Endoscopic Rendezvous Procedure for Cholelithiasis with Choledocholithiasis: A Retrospective Cohort Study.” Therapeutics and clinical risk management (2026). PMID: 41859199 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [30]
Liu J, Xu H, Huang C et al.. “Admission HDL-C and recurrence risk of hypertriglyceridemia-induced acute pancreatitis: a multicenter cohort study.” Frontiers in nutrition (2026). PMID: 41693951 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [31]
Dayan-Rosenman D, Diletti-Swenson S, Ghayalod N et al.. “Iatrogenic physiologic opioid dependence masquerading as recurrent acute pancreatitis flares: case series.” Addiction science & clinical practice (2026). PMID: 41680940 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [32]
Maringhini A, Patti R, Maringhini M et al.. “Ursodeoxycholic Acid for the Prevention of Relapse of Pregnancy-Related Acute Gallstone Pancreatitis.” Journal of clinical medicine (2026). PMID: 41976880 ↗
L5OTHERCited in: Etiology and Triggering Factors - [33]
Deng F, Ding L, Du YY et al.. “Low-molecular-weight heparin and respiratory failure in hypertriglyceridemia-associated acute pancreatitis.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41968002 ↗
L5OTHERCited in: Etiology and Triggering Factors - [34]
Li Y, Wang Y, Wan X et al.. “Radiomics derived from MRI T2-weighted imaging combined with clinical variables for predicting disease severity in hypertriglyceridemic acute pancreatitis.” Abdominal radiology (New York) (2026). PMID: 41925844 ↗
L5OTHERCited in: Etiology and Triggering Factors - [35]
Sirtl S, Ahmad M, Allawadhi P et al.. “NLRP3 Inflammasome Activation-Induced Acute Papillitis as a Trigger of Acute Pancreatitis - A Novel Mechanism of Microlithiasis-Induced Acute Pancreatitis.” United European gastroenterology journal (2026). PMID: 41830600 ↗
L5OTHERCited in: Etiology and Triggering Factors - [36]
Ozkaya M, Atik I, Ozkaya S et al.. “Incidence and clinical significance of biliary and pancreatic duct variations on magnetic resonance cholangiopancreatography.” Abdominal radiology (New York) (2026). PMID: 41801378 ↗
L5OTHERCited in: Etiology and Triggering Factors - [37]
Faraci S, Rollo G, Alghisi F et al.. “ERCP-based management of pediatric chronic pancreatitis: Results from a retrospective long-term multicentric study.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2026). PMID: 41723027 ↗
L5OTHERCited in: Etiology and Triggering Factors - [38]
Liu Z, He Y, Chen Z et al.. “Pleural effusion within 24 h of admission predicts severe hypertriglyceridemia-induced acute pancreatitis and organ failure: retrospective cohort of 296 patients.” Frontiers in medicine (2026). PMID: 41658612 ↗
L5OTHERCited in: Etiology and Triggering Factors - [39]
Peng Q, Long Y, Yang K et al.. “Prognostic analysis of acute pancreatitis due to different etiologies and establishment and validation of an early prediction model.” Lipids in health and disease (2026). PMID: 41645226 ↗
L5OTHERCited in: Etiology and Triggering Factors - [40]
Spoială EL, Oltean C, Vasiliu I et al.. “Multimodal Management of Extreme Hypertriglyceridemia in a Child with Recurrent Pancreatitis: Clinical Challenges and Solutions.” Journal of clinical medicine (2026). PMID: 41598575 ↗
L5OTHERCited in: Etiology and Triggering Factors - [41]
Krajewska A, Tłustochowicz K, Kowalik A et al.. “Comparison of the Clinical Course, Management and Outcomes of Acute Pancreatitis in Aged and Young Patients.” Biomedicines (2026). PMID: 41595672 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, History and Physical Examination - [42]
Chiriac S, Sfarti C, Minea H et al.. “Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Bile Duct Stones-Avoiding the Avoidable.” Biomedicines (2026). PMID: 41595627 ↗
L5OTHERCited in: Etiology and Triggering Factors - [43]
Choudhary A, James A, Dahake U et al.. “Therapeutic plasmapheresis in a young infant with severe hypertriglyceridemia: a case report.” Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology (2026). PMID: 41923786 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [44]
Takasu S, Nakagawa M, Matsumoto S. “Autopsy case of a possible enigmatic triad accompanied by black esophagus and Wischnewsky spots.” Legal medicine (Tokyo, Japan) (2026). PMID: 41774981 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [45]
Vega J, Torres B, Maiz A et al.. “Case Report: Conventional therapy versus volanesorsen in two sisters with familial chylomicronemia syndrome.” Frontiers in nutrition (2026). PMID: 41737337 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [46]
Bodnar C, Hughey C, Bodker A et al.. “Milky Plasma, Murky Diagnosis: Urgent Plasma Exchange for Severe Hypertriglyceridemia-Induced Hyperviscosity Without Pancreatitis, but With Myocardial Infarction.” Journal of clinical apheresis (2026). PMID: 41709485 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [47]
Liu T, Cao Z, Lai F et al.. “Case Report: Vincristine-induced acute pancreatitis in pediatric Wilms tumor: first reported case challenging previous risk classifications and proposing vigilant monitoring protocols.” Frontiers in pediatrics (2025). PMID: 41602884 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [48]
Wang Z, Liu Y, Ren P et al.. “A prognostic model based on metabolic indicators for recurrent acute pancreatitis in hypertriglyceridemia patients: a retrospective cohort study.” Annals of medicine (2026). PMID: 41978916 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [49]
Gondal AN, Ahmed P, Akram F et al.. “Evaluation of Acute Pancreatitis in Patients Receiving Doxycycline Therapy: A Prospective Study.” Cureus (2026). PMID: 41646617 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [50]
Popa SL, Incze V, Ismaiel A et al.. “Non-Infectious Causes for Elevated Procalcitonin.” Medicina (Kaunas, Lithuania) (2026). PMID: 41901546 ↗
L2aSR_OBSCited in: Pathophysiology - [51]
Yang X, Zhang L, Lin H et al.. “Early oral anti-inflammatory diet in patients with mild acute pancreatitis: study protocol for a randomized controlled trial.” Trials (2026). PMID: 41668182 ↗
L2bTRIAL_NONRANDOMCited in: Pathophysiology - [52]
Yan H, Dang X, Du G et al.. “IL-35, IL-37, and IL-38 in acute pancreatitis: proposed immunopathogenic mechanisms and therapeutic potential.” Frontiers in immunology (2026). PMID: 41737213 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology, Supportive Care and Complication Management - [53]
Tun HN, Rahal O, Figueroa Baez IR et al.. “Heart failure with preserved ejection fraction beyond the heart: exploring the heart-liver-pancreas axis.” ESC heart failure (2026). PMID: 41711215 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [54]
Zhang J, Chen H, Wang Y et al.. “Cell death and its interaction with mitochondrial dysfunction in pathogenesis of acute pancreatitis: a comprehensive review.” Apoptosis : an international journal on programmed cell death (2026). PMID: 41663764 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [55]
Kurt SZE, Kurt E, Isin MS et al.. “The diagnostic value of the systemic immune-inflammation index in acute pancreatitis: a retrospective cohort study.” Irish journal of medical science (2026). PMID: 41926028 ↗
L2bCOHORTCited in: Pathophysiology - [56]
Ma H, Li N, Zhang H et al.. “The association between inflammatory indices and acute pancreatitis severity: a retrospective cohort study.” Frontiers in surgery (2026). PMID: 41835252 ↗
L2bCOHORTCited in: Pathophysiology - [57]
Chooklin S, Chuklin S. “Nanotherapy for acute pancreatitis: a systematic review of experimental strategies and mechanisms of action.” Discover nano (2026). PMID: 41661463 ↗
L2aSR_OBSCited in: Pathophysiology - [58]
Wang Y, Ma L, Jiang Y et al.. “Revealing the temporal metabolic trajectory and potential pharmacodynamic substances of Da-Cheng-Qi Decoction in treating patients with acute pancreatitis: A serum metabolomics-based study.” Journal of ethnopharmacology (2026). PMID: 41825726 ↗
L1bRCTCited in: Pathophysiology - [59]
Alsaleh T, George J. “Targeted therapeutics for pancreatitis.” Frontiers in physiology (2026). PMID: 41907532 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [60]
Chooklin S, Chuklin S. “Beyond Supportive Care: Mitochondria as a Strategic Therapeutic Avenue in Acute Pancreatitis.” Digestive diseases and sciences (2026). PMID: 41854947 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [61]
Chooklin S, Chuklin S. “Interleukin-22 in acute pancreatitis: Balancing damage and repair.” Hepatobiliary & pancreatic diseases international : HBPD INT (2026). PMID: 41763954 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [62]
Chooklin S, Chuklin S. “Breaking the Calcium Overload Cycle in Acute Pancreatitis: Emerging Pharmacological Strategies.” Digestive diseases and sciences (2026). PMID: 41703270 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [63]
Dai NN, Geng ZG, Wang J et al.. “Pancreas-brain axis: exploring the pathogenic mechanisms of pancreatic encephalopathy.” International immunopharmacology (2026). PMID: 41689875 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [64]
Feng X, Lin J. “Advances in Glucocorticoid Therapy for Acute Pancreatitis: A Review.” Pancreas (2026). PMID: 41677367 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [65]
Xu K, Han Y, Chen F et al.. “Dose-dependent dissociation between intestinal protection and pancreatic outcome following licochalcone A treatment in severe acute pancreatitis.” Frontiers in pharmacology (2026). PMID: 41971086 ↗
L5OTHERCited in: Pathophysiology - [66]
Li H, Zhang X, He Z et al.. “Disruption of the Circadian Rhythm Induces Acute Pancreatitis via Amino Acid Metabolism-Mediated Macrophage Infiltration.” Cellular and molecular gastroenterology and hepatology (2026). PMID: 41903683 ↗
L5OTHERCited in: Pathophysiology - [67]
Guan L, Li X, He C et al.. “Bifidobacterium Pseudolongum-Derived Acetate Attenuates Acute Pancreatitis Through GPR43-Mediated Suppression of M1 Macrophage Polarization.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID: 41903115 ↗
L5OTHERCited in: Pathophysiology - [68]
Uppal M, Neredimelli SK, Yadav HN et al.. “Development of an experimental model of severe acute pancreatitis with organ failure.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41881753 ↗
L5OTHERCited in: Pathophysiology, Supportive Care and Complication Management - [69]
Cheng L, Jiang C, Jiang W et al.. “Influences of probiotics plus enteral nutrition on intestinal flora and inflammatory response in patients with severe acute pancreatitis.” Frontiers in medicine (2026). PMID: 41877788 ↗
L5OTHERCited in: Pathophysiology - [70]
Joseph N, Kuhlmann L, Lucocq J et al.. “A Systematic Review of Pain Assessment Domains in Acute Pancreatitis Randomized Controlled Trials.” Pancreas (2026). PMID: 40748823 ↗
L1aSR_MA_RCTCited in: History and Physical Examination - [71]
Dobszai D, Obeidat M, Szalai EÁ et al.. “Metabolic syndrome components individually worsen the outcome of acute pancreatitis: a systematic review and meta-analysis.” Frontiers in endocrinology (2025). PMID: 41262260 ↗
L2aSR_OBSCited in: History and Physical Examination - [72]
Anderloni A, Spadaccini M, Binda C et al.. “Endoscopic Ultrasound-Guided Choledochoduodenostomy vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction to Prevent Postprocedural Pancreatitis: A Randomized Trial.” Gastroenterology (2026). PMID: 41511419 ↗
L1bRCTCited in: History and Physical Examination - [73]
Gan W, Zhang W, Cai J et al.. “A Multicenter Study of Acute Abdomen in Children With Acute Lymphoblastic Leukemia: CCCG-ALL-2015.” Cancer medicine (2025). PMID: 40842042 ↗
L1bRCTCited in: History and Physical Examination - [74]
Han Y, Zhao H, Fu L et al.. “The utilization of oral feeding in pediatric pancreatitis: a randomized controlled study.” Jornal de pediatria (2026). PMID: 41620210 ↗
L1bRCTCited in: History and Physical Examination - [75]
Wan J, Xiong S, Zou Y et al.. “Cumulative burden and dynamic trajectories of heart rate as predictors of prognosis in acute pancreatitis: an 18-year cohort study.” International journal of surgery (London, England) (2026). PMID: 40990508 ↗
L2bCOHORTCited in: History and Physical Examination - [76]
Kerbage A, Brunaldi VO, Al Annan K et al.. “Impact of Metabolic Surgery on the Severity and Outcomes of Acute Pancreatitis: A Retrospective Matched Cohort Study.” Obesity surgery (2025). PMID: 40804224 ↗
L2bCOHORTCited in: History and Physical Examination - [77]
Palermo TM, Ohls O, Dear B et al.. “Digital cognitive-behavioral therapy for pain management in individuals with recurrent acute and chronic pancreatitis (IMPACT-2): study protocol for a hybrid effectiveness-implementation trial.” Trials (2026). PMID: 41664170 ↗
L2bTRIAL_NONRANDOMCited in: History and Physical Examination - [78]
Jalleh RJ, Talley NJ, Horowitz M et al.. “The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications.” The Journal of clinical investigation (2026). PMID: 41697736 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [79]
Tayier D, Wang K, Yuan Y et al.. “Research Status on the Effects of Obesity on Acute Pancreatitis.” Obesity reviews : an official journal of the International Association for the Study of Obesity (2026). PMID: 40751382 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [80]
Wang YX, Ge P, Chen HL. “Induction of hyperlipidemic pancreatitis by different fatty acids: A narrative review.” World journal of gastroenterology (2025). PMID: 40539203 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [81]
Zhu Q, Shan X, Tan D et al.. “Risk factor analysis and nomogram development for survival prediction in obese patients with severe acute pancreatitis: a retrospective study.” BMC gastroenterology (2025). PMID: 41013263 ↗
L2bCOHORTCited in: History and Physical Examination - [82]
Jaya Pragadeesh G, Abu Sali SA, Rajesh Kumar S et al.. “Gliptin induced acute pancreatitis: a literature review.” Acta gastro-enterologica Belgica (2025). PMID: 40504582 ↗
L2aSR_OBSCited in: History and Physical Examination - [83]
Mohamadnejad M, Hassanzadeh M, Anushirvani A et al.. “Immediate vs On-Demand Endoscopic Necrosectomy in Infected Walled-Off Pancreatic Necrosis: A Randomized Controlled Trial.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 41722664 ↗
L1bRCTCited in: Supportive Care and Complication Management - [84]
Eperjesi O, Bucur M, Rancz A et al.. “Risk factors for pancreatic exocrine insufficiency after acute pancreatitis: A systematic review and meta-analysis.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41807143 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [85]
Chooklin S, Chuklin S. “Neutrophil-to-lymphocyte ratio for primary risk stratification in acute pancreatitis: a systematic review and meta-analysis.” Frontiers in medicine (2025). PMID: 41608433 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [86]
Ren Y, Xia L, Luo L et al.. “Early direct admission to tertiary hospital specialized care reduces risk of severe acute pancreatitis: A propensity score-matched retrospective cohort study.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41692636 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [87]
Xu X, He C, Ding L et al.. “The similarity between microbiota of gut and pancreatic necrotic drainage fluid in infected pancreatic necrosis and its potential diagnostic value: a prospective observational cohort study.” BMC microbiology (2026). PMID: 41612182 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [88]
Shahzil M, Faisal MH, Khan MH et al.. “Comparative efficacy and safety of bi-flanged metal stents versus lumen-apposing metal stents for endoscopic drainage of pancreatic fluid collections: a systematic review and meta-analysis.” European journal of gastroenterology & hepatology (2026). PMID: 41925047 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [89]
Shakeev K, Klyuyev D, Ogizbayeva A et al.. “Comparative Evaluation of the Prognostic Accuracy of IL-6 and Angiopoietin-2 for Early Severity Assessment in Acute Pancreatitis: A Systematic Review.” Diseases (Basel, Switzerland) (2026). PMID: 41590239 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [90]
Qi R, Zhong J, Wang H et al.. “Nomogram for Predicting Pancreatic Pseudocyst in Hypertriglyceridemic Acute Pancreatitis: A Retrospective Cohort Study.” Journal of inflammation research (2026). PMID: 41982474 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [91]
Lew C, Jones M, Pham H et al.. “Outcomes of Patients With Severe Acute Pancreatitis Requiring Prolonged Intensive Care Admission at a Tertiary Centre: A Retrospective Cohort Study.” ANZ journal of surgery (2026). PMID: 41823127 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [92]
Cao Y, Li W, Peng P et al.. “Development and validation of an early prediction model for hypertriglyceridaemic severe acute pancreatitis: a retrospective study.” PeerJ (2026). PMID: 41584837 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [93]
Xu H, Zhang Z, Yang Y et al.. “Partial hepatectomy for pancreatic-origin hepatic abscess with intracystic hemorrhage following severe acute pancreatitis: a case report.” Frontiers in medicine (2026). PMID: 41868209 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [94]
Iacob A, Balan GG, Blaj M et al.. “Fungal Infections in Severe Acute Pancreatitis: Insights from a Case Series.” Journal of clinical medicine (2026). PMID: 41598727 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [95]
Tsuyama T, Suenaga S, Suehiro H et al.. “Lumen-apposing metal stent for peripancreatic fluid collection contributes to early improvement of nutritional status: A multicenter retrospective study (YCR-P001).” Medicine (2026). PMID: 41824843 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [96]
Zhang X, Peng K, Peng Y et al.. “Serum GAS6 is useful biomarker for identifying patients with severe acute pancreatitis within 24 h of admission: a multi-cohort analysis of 869 patients.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41956867 ↗
L5OTHERCited in: Supportive Care and Complication Management - [97]
Feng H, Wang P, He W et al.. “Development and interpretable machine learning models for classification of pancreatic pseudocyst risk in acute pancreatitis.” Frontiers in digital health (2026). PMID: 41924180 ↗
L5OTHERCited in: Supportive Care and Complication Management - [98]
Zhu P, Fang W, Tu H. “Development and validation of a nomogram model for predicting unplanned readmission in patients with acute pancreatitis.” Frontiers in endocrinology (2026). PMID: 41890191 ↗
L5OTHERCited in: Supportive Care and Complication Management - [99]
Lu H, Shen H, Cui J et al.. “Rhein attenuates severe acute pancreatitis-associated intestinal injury through PPARγ regulating macrophage activation.” Chinese medical journal (2026). PMID: 41859859 ↗
L5OTHERCited in: Supportive Care and Complication Management - [100]
Pauw HS, Schwarz R, Beij A et al.. “Antimicrobial therapy for infected necrotizing pancreatitis: microbiology, antimicrobial resistance and pharmacokinetics.” The Journal of antimicrobial chemotherapy (2026). PMID: 41808660 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [101]
Kitagawa K, Asada S, Hanatani JI et al.. “Multi-Hole Self-Expandable Metallic Stent for Malignant Distal Biliary Obstruction: A Literature Review.” Journal of clinical medicine (2026). PMID: 41753098 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [102]
Fernandez Y Viesca M, Hadefi A, Otero Sanchez L et al.. “Risk Factors Associated with the Emergence of Multidrug-Resistant Bacteria and Fungal Infections in Walled-Off Pancreatic Necrosis.” Antibiotics (Basel, Switzerland) (2026). PMID: 41750517 ↗
L5OTHERCited in: Supportive Care and Complication Management - [103]
Yamashita Y, Kitano M. “EUS-guided pancreatic duct drainage-technical tips and outcomes: narrative review.” Therapeutic advances in gastroenterology (2026). PMID: 41732329 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [104]
Ma S, Qin J, Luan J et al.. “Targeting mitochondrial phosphatase PGAM5 alleviates ferroptosis and acute pancreatitis by upregulating NRF2-mediated FSP1 expression.” Cell death & disease (2026). PMID: 41723122 ↗
L5OTHERCited in: Supportive Care and Complication Management - [105]
Siriwardena AK. “A Practical Guide to the Roles of Procalcitonin Measurement in Patients with Acute Pancreatitis.” Journal of clinical medicine (2026). PMID: 41682834 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [106]
Cárdenas-Jaén K, Guilabert L, Martínez-Moneo E et al.. “AEG-AESPANC-OPGE-SIED-SPG Ibero-Latin American Guidelines on Acute Pancreatitis (iLATAM-AP).” United European gastroenterology journal (2026). PMID: 42216617 ↗
L1aCited in: Definition, Synonyms, and Classification - [107]
Kudchadkar S, Peddakota V, Mudavath LC et al.. “Systematic Review of Role of Oxidative Stress and Clinical Implications in Acute Pancreatitis.” World journal of surgery (2026). PMID: 42438222 ↗
L2aCited in: Definition, Synonyms, and Classification - [108]
Wang F, Huang Z, Xue Z et al.. “APEX-NET: automated pancreatic evaluation network using early non-contrast CT.” European radiology (2026). PMID: 42377437 ↗
L2bCited in: Definition, Synonyms, and Classification - [109]
Madela F, Chiliza K, Mfeka X et al.. “Correlation between immune biomarkers and surrogate markers of severity of Acute Pancreatitis in an HIV endemic region.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2025). PMID: 41314904 ↗
L2bCited in: Definition, Synonyms, and Classification - [110]
Hubert MO, Ahmad M, Crispin A et al.. “Meta-Analysis Obesity Correlates with Severity and Mortality in Acute Pancreatitis: An Updated Meta-Analysis.” Digestive diseases (Basel, Switzerland) (2026). PMID: 42139165 ↗
L2aCited in: Definition, Synonyms, and Classification - [111]
Rantsev M, Sarapultsev A, Chereshnev V. “Neuromodulatory Interventions in Experimental Acute Pancreatitis: A Systematic Review of Rodent Studies.” Diseases (Basel, Switzerland) (2026). PMID: 42041637 ↗
L2aCited in: Definition, Synonyms, and Classification - [112]
Yavuz A, Ebik B, Karabulut Ü et al.. “Evaluation of the Admission Neutrophil Percentage-to-Albumin Ratio for Predicting the Severity of Acute Pancreatitis.” Biomedicines (2026). PMID: 42512016 ↗
L3bCited in: Definition, Synonyms, and Classification - [113]
Yu M, Mao E, Xu Y et al.. “Triglyceride Threshold for Intensive Lipid-Lowering Therapy in Acute Hyper-Triglyceridemic Pancreatitis: A Retrospective Study.” Journal of clinical medicine (2026). PMID: 42355749 ↗
L3bCited in: Definition, Synonyms, and Classification - [114]
Wei W, Wang Y, Xie P et al.. “Development of a prediction method for severe pancreatitis using a nomogram.” Frontiers in medicine (2026). PMID: 42180752 ↗
L3bCited in: Definition, Synonyms, and Classification - [115]
Chiarello MM, Fico V, Misuriello F et al.. “Are BISAP and APACHE II scores still useful to identify high-risk patients in acute pancreatitis? A retrospective multicenter analysis on 450 patients.” Updates in surgery (2026). PMID: 42166093 ↗
L3bCited in: Definition, Synonyms, and Classification - [116]
Hao X, Feng X, Liu F et al.. “Real-time guidance of lauromacrogol ablation for pancreatic cystic lesions using confocal laser endomicroscopy.” Therapeutic advances in gastroenterology (2026). PMID: 41705165 ↗
L3bCited in: Definition, Synonyms, and Classification - [117]
Xu X, Xu T, Wang Y et al.. “Clinical value of BISAP score combined with low-density lipoprotein cholesterol and ascites in early prediction of hypertriglyceridemic severe acute pancreatitis.” Frontiers in endocrinology (2025). PMID: 41446633 ↗
L3bCited in: Definition, Synonyms, and Classification - [118]
Saullo P, Caronna R, Angelici AM et al.. “Value of Continuous Hemofiltration in Patients with Severe Acute Pancreatitis at Onset: Single Centre Experience on 48 Patients.” Journal of clinical medicine (2025). PMID: 41010851 ↗
L3bCited in: Definition, Synonyms, and Classification - [119]
Masson W, Lobo M, Mansur M et al.. “Clinical effects of apolipoprotein C3 inhibitors on triglyceride levels and pancreatitis risk: a systematic review and meta-analysis.” Minerva endocrinology (2026). PMID: 42329673 ↗
L1aCited in: Etiology and Triggering Factors - [120]
Liang AC, Castillo YC, Bruciaga LMM et al.. “Comparative Efficacy of Insulin and Alternative Therapies for Hypertriglyceridemia-Associated Acute Pancreatitis: A Systematic Review and Network Meta-Analysis.” Digestive diseases and sciences (2026). PMID: 42301369 ↗
L1aCited in: Etiology and Triggering Factors - [121]
Gad MM, Ayad Q, Elgamal MM et al.. “Cholecystectomy versus conservative management for patients with uncomplicated symptomatic gallstones and cholecystitis: an updated systematic review and meta-analysis.” BMC surgery (2026). PMID: 42265664 ↗
L1aCited in: Etiology and Triggering Factors - [122]
Shen Y, Bai Y. “Rectal Nonsteroidal Anti-Inflammatory Drugs, Aggressive Hydration With Lactated Ringer's Solution, Somatostatin or Combinations for Prophylaxis Post-ERCP Acute Pancreatitis: A Network Meta-Analysis.” Pancreas (2026). PMID: 42240446 ↗
L1aCited in: Etiology and Triggering Factors - [123]
Soran H, Kessler AS, Vera-Llonch M et al.. “Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison.” Journal of comparative effectiveness research (2026). PMID: 42319369 ↗
L1bCited in: Etiology and Triggering Factors - [124]
Tarar ZI, Gandhi M, Farooq U et al.. “Prophylactic biliary stenting post-ERCP prior to cholecystectomy: a systematic review and meta-analysis.” Surgical endoscopy (2026). PMID: 42443680 ↗
L2aCited in: Etiology and Triggering Factors - [125]
Shaaban Abdelgalil M, Abdelrazek A, Mohamed MS et al.. “EUS-guided hepaticogastrostomy versus EUS-guided hepaticogastrostomy with antegrade stent placement in patients with unresectable malignant distal biliary obstruction: a meta-analysis of individual patient data.” BMC gastroenterology (2026). PMID: 42436411 ↗
L2aCited in: Etiology and Triggering Factors - [126]
Liu J, Yu Y, Qiu X et al.. “Baseline current smoking and time-varying recurrence risk after first-episode of hypertriglyceridemia-induced acute pancreatitis: A multicenter retrospective cohort study.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 42570923 ↗
L3bCited in: Etiology and Triggering Factors - [127]
Li J, Liu X, Zhao R et al.. “Analysis of the association between the neutrophil-to-lymphocyte ratio (NLR) and liver injury complicating acute pancreatitis: a retrospective study.” Frontiers in medicine (2026). PMID: 42559316 ↗
L3bCited in: Etiology and Triggering Factors - [128]
Ain Q, Huda NU, Khan M et al.. “Prevalence and clinical characteristics of probable familial chylomicronaemia syndrome at a tertiary care center in Pakistan: Insights from a hospital-based screening study.” Journal of clinical lipidology (2026). PMID: 42538190 ↗
L3bCited in: Etiology and Triggering Factors - [129]
Uemura S, Iwashita T, Koizumi T et al.. “Visceral Adipose Tissue as an Independent Predictor of Severe Post-ERCP Pancreatitis: A Multicenter Retrospective Cohort Study.” Journal of hepato-biliary-pancreatic sciences (2026). PMID: 42494284 ↗
L3bCited in: Etiology and Triggering Factors - [130]
Yang S, Li C, Zeng K et al.. “Development and validation of a 24-h predictive model for hypertriglyceridemic moderately severe acute pancreatitis: a single-center retrospective study.” Frontiers in medicine (2026). PMID: 42465082 ↗
L3bCited in: Etiology and Triggering Factors - [131]
Selin D, Oskarsson V, Maret-Ouda J et al.. “Cholecystectomy vs Endoscopic Retrograde Cholangiopancreatography or No Intervention After Gallstone-Related Acute Pancreatitis.” JAMA surgery (2026). PMID: 42340741 ↗
L3bCited in: Etiology and Triggering Factors - [132]
Guo Q, Chen W, Qin K et al.. “Integrating 2.5D multi-modal CT imaging with serum triglycerides for early risk stratification in hypertriglyceridemia-induced acute pancreatitis: A multicenter study.” European journal of radiology (2026). PMID: 42322722 ↗
L3bCited in: Etiology and Triggering Factors - [133]
Liu Z, Li Z, Liu D et al.. “Clinical outcomes of immediate, 24-h, and 24-72-h laparoscopic cholecystectomy after endoscopic stone clearance: a matched cohort analysis.” Surgical endoscopy (2026). PMID: 42257960 ↗
L3bCited in: Etiology and Triggering Factors - [134]
Liu F, Liu XQ, Gu DJ et al.. “Laparoscopic common bile duct exploration and primary suture versus ERCP combined with laparoscopic cholecystectomy for choledocholithiasis: a retrospective comparative study.” Surgical endoscopy (2026). PMID: 42257936 ↗
L3bCited in: Etiology and Triggering Factors - [135]
An J, Zhang G, Zhou X. “A prognostic model based on integrated clinical indicators for recurrent acute pancreatitis in patients with hypertriglyceridemia: a retrospective cohort study.” Lipids in health and disease (2026). PMID: 42249448 ↗
L3bCited in: Etiology and Triggering Factors - [136]
Yao W, Zhao C, Cao L et al.. “Development and Validation of an Early Severity Prediction Model for Hypertriglyceridemia-Associated Acute Pancreatitis: A Multicenter Cohort Study.” Journal of inflammation research (2026). PMID: 42375817 ↗
L2bCited in: Etiology and Triggering Factors - [137]
Zhao G, Wang Y, Zhang G et al.. “Risk factors for post-ERCP pancreatitis and assessment of stent exchange intervals in children with chronic pancreatitis: a single-center retrospective study.” BMC pediatrics (2026). PMID: 42343307 ↗
L2bCited in: Etiology and Triggering Factors - [138]
Nishimura M, Miwa H, Kaneko T et al.. “Post-Endoscopic Retrograde Cholangiopancreatography Bleeding After Endoscopic Stone Removal in Dialysis Patients: A Multicenter Retrospective Study.” DEN open (2026). PMID: 42569438 ↗
L4Cited in: Etiology and Triggering Factors - [139]
Wang L, Nie Z, Huang Q. “Effect of a structured early rehabilitation program on long-term functional recovery, quality of life, and survival in patients with severe acute pancreatitis: a randomized controlled trial.” BMC gastroenterology (2026). PMID: 42204448 ↗
L1bCited in: Pathophysiology - [140]
Tian H, Wang L, He Z et al.. “Global landscape and knowledge structure of research on pancreatitis and gut microbiota: a bibliometric analysis based on WoSCC and Scopus (2006 - 2025).” Frontiers in cellular and infection microbiology (2026). PMID: 42568357 ↗
L2aCited in: Pathophysiology - [141]
Pakai E, Klonfar K, Walter A et al.. “Fever on hospital admission is associated with increased disease severity and mortality in acute pancreatitis: a systematic review and meta-analysis.” Systematic reviews (2026). PMID: 42482129 ↗
L2aCited in: Pathophysiology - [142]
Naz F, Qaiser F, Mumtaz A et al.. “Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.” Medicine (2026). PMID: 42536519 ↗
L1aCited in: Pathophysiology - [143]
Sang H, Liu X, Song J. “Visceral adipose tissue and acute pancreatitis: a systematic review and meta-analysis.” PeerJ (2026). PMID: 42254660 ↗
L2aCited in: Pathophysiology - [144]
Ben Ismail I, Sghaier M, Zenaidi H et al.. “The Neutrophil-Creatinine Index as an Early Predictor of Severe Acute Pancreatitis.” The Journal of surgical research (2026). PMID: 42556197 ↗
L3bCited in: Pathophysiology - [145]
Pădureanu V, Florescu DN, Cazacu SM et al.. “Evaluation of oxidative stress in acute pancreatitis.” Frontiers in immunology (2026). PMID: 42220490 ↗
L3bCited in: Pathophysiology - [146]
Huang A, Yuan Q, Chen J et al.. “Deep chemical structure graph learning deciphers the lipotoxicity code of hypertriglyceridemic pancreatitis.” NPJ digital medicine (2026). PMID: 42204286 ↗
L3bCited in: Pathophysiology - [147]
Gu H, Tang C, Shi Y et al.. “sEV-Enriched Serum Preparations From Healthy Individuals Protect Against Acute Pancreatitis-Induced Intestinal Barrier Dysfunction Through miR-579-3p/ANXA3-Mediated Inhibition of NLRP3 Inflammasome Pyroptosis.” Archivum immunologiae et therapiae experimentalis (2026). PMID: 42347491 ↗
L3bCited in: Pathophysiology - [148]
Chen X, Li Z, Mao T et al.. “Predictive value of sarcopenia-related clinical indices for early disease progression in acute pancreatitis: a multicenter retrospective cohort study.” Frontiers in nutrition (2026). PMID: 42564036 ↗
L3bCited in: Pathophysiology - [149]
Wen Y, Chen W, Zhang W et al.. “The Correlation Analysis of C-Reactive Protein-Triglyceride-Glucose Index with the Severity of Hyperlipidemic Acute Pancreatitis.” Digestive diseases and sciences (2026). PMID: 42474624 ↗
L3bCited in: Pathophysiology - [150]
Wang Z, Liu Y, Li C. “Nutritional modulation of disease severity in acute pancreatitis: metabolic pathways, inflammatory signaling, and diet-responsive clinical outcomes.” Frontiers in nutrition (2026). PMID: 42459810 ↗
L3bCited in: Pathophysiology - [151]
Yu W, Yang P, Ding M et al.. “Acute pancreatitis temporally associated with COVID-19 pneumonia in a patient with post-tuberculosis chronic pulmonary aspergillosis: a case report.” Frontiers in medicine (2026). PMID: 42344497 ↗
L4Cited in: Pathophysiology - [152]
Ambli S, Gupta BK, Pandey AR et al.. “Comparison of the incidence of acute kidney injury in patients with acute pancreatitis managed with or without thoracic epidural analgesia: A prospective randomized controlled trial.” International journal of critical illness and injury science (2026). PMID: 42281814 ↗
L1bCited in: Pathophysiology - [153]
Turkmen B, Özel Yetkin M, Yenişekerci Kulak E et al.. “The Global Immune-Nutrition-Inflammation Index (GINI) in Acute Pancreatitis Severity Assessment: A Comparative Study.” Digestive diseases and sciences (2026). PMID: 42570998 ↗
L3bCited in: Pathophysiology - [154]
Cohen BD, Eluri N, Levine S et al.. “Atrial fibrillation and cardiovascular comorbidity burden as predictors of in-hospital mortality in acute pancreatitis: A National Inpatient Sample analysis of 1.9 million hospitalizations.” International journal of cardiology. Cardiovascular risk and prevention (2026). PMID: 42382912 ↗
L3bCited in: Pathophysiology - [155]
Mareninova OA, Chang AG, Hernandez Malpica S et al.. “Genetic and pharmacologic modulations elucidate NRF2 protective role in acute pancreatitis.” American journal of physiology. Gastrointestinal and liver physiology (2026). PMID: 42530545 ↗
L5Cited in: Pathophysiology - [156]
Pandanaboyana S, Knoph CS, Kuhlmann L et al.. “European Interdisciplinary Guidelines on Pain Management in Acute Pancreatitis: UEG, EPC, EDS, ESDO, EAGEN, ESPGHAN, ESGAR, and ESPCG Evidence-Based Recommendations.” United European gastroenterology journal (2026). PMID: 42299777 ↗
L1cCited in: History and Physical Examination - [157]
Hammad N, Ramadan AM, Nazmy A et al.. “Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis.” Diabetes technology & therapeutics (2026). PMID: 41640110 ↗
L1aCited in: History and Physical Examination - [158]
Aguilar-Salinas CA, Alonso R, Berg G et al.. “A multi-society Delphi consensus statement on the diagnosis of familial chylomicronemia syndrome.” Archives of endocrinology and metabolism (2025). PMID: 41026863 ↗
L1cCited in: History and Physical Examination - [159]
Liu Y, Feng XY, Chen C et al.. “Nutritional recovery after minimally invasive pancreatic stone treatment: Body mass index dynamics and predictors in chronic pancreatitis cohorts.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2026). PMID: 42108155 ↗
L2bCited in: History and Physical Examination - [160]
López FV, Kesavan P, Win LK et al.. “Hyperamylasaemia in paediatric inflammatory bowel disease: Aetiology, outcomes and genetic determinants.” Journal of pediatric gastroenterology and nutrition (2026). PMID: 42037072 ↗
L4Cited in: History and Physical Examination - [161]
Kuhlmann L, Davidsen L, Knoph CS et al.. “Trajectories of Pain Processing in Recurrent Acute and Chronic Pancreatitis: A Longitudinal Quantitative Sensory Testing Study.” European journal of pain (London, England) (2026). PMID: 41842672 ↗
L4Cited in: History and Physical Examination - [162]
Gao L, Zhang R, Xiao Y et al.. “High Serum Lipase Level is Associated With Increased Analgesic Use in Hospitalized Patients With Acute Pancreatitis.” Pain research & management (2026). PMID: 41808845 ↗
L3bCited in: History and Physical Examination - [163]
Tartaglia E, Bucci T, Rossi M et al.. “Risk of all-cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research network.” Cardiovascular diabetology (2025). PMID: 41257737 ↗
L3bCited in: History and Physical Examination - [164]
Gu RJ, Zhang YR. “Predictive utility of the triglyceride-glucose index and visceral adiposity-related indices for severe progression in hypertriglyceridemic pancreatitis.” Journal of clinical lipidology (2025). PMID: 41162245 ↗
L3bCited in: History and Physical Examination - [165]
Tarján D, Szalai EÁ, Erőss B et al.. “Safety and Effectiveness of Cholecystectomy and Endoscopic Retrograde Cholangiopancreatography in Biliary Pancreatitis During Pregnancy: BORN Study.” United European gastroenterology journal (2025). PMID: 41045491 ↗
L4Cited in: History and Physical Examination - [166]
Zhou AL, Chiang JY, Chan KS et al.. “Decoding Alexander the Great's gastrointestinal cause of death using artificial wisdom: An artificial intelligence-human inquiry into a medical mystery.” World journal of gastroenterology (2025). PMID: 41479650 ↗
L3bCited in: History and Physical Examination - [167]
Barbar M, Kanaan D, AlZebin Z et al.. “Severe asparaginase-associated hypertriglyceridemia in pediatric acute lymphoblastic leukemia: a single-center experience.” Frontiers in oncology (2026). PMID: 42415868 ↗
L4Cited in: History and Physical Examination - [168]
Yu B, Li Y, Li N et al.. “Age-related vulnerability and clinical outcomes in acute pancreatitis: a stratified cohort study of 1,034 patients.” BMC gastroenterology (2026). PMID: 42304224 ↗
L3bCited in: History and Physical Examination - [169]
Cui N, Wang W, Xu W. “Therapeutic Outcomes and Risks of Plasmapheresis in Hypertriglyceridemia Acute Pancreatitis: A Systematic Review and Meta-analysis.” Digestion (2026). PMID: 42647439 ↗
L1aCited in: Etiology and Triggering Factors - [170]
Yao Y, Yuan B, Wang K et al.. “An explainable machine learning framework integrating clinical and lipidomic signatures for early severity stratification of hypertriglyceridemic pancreatitis.” Frontiers in medicine (2026). PMID: 42638867 ↗
L2bCited in: Etiology and Triggering Factors - [171]
Warfield MN, Cole KC, Heybati K et al.. “Safety of Coadministration of Continuous Infusions of Propofol and Clevidipine: A Multi-Site Retrospective Analysis.” Pharmacotherapy (2026). PMID: 42666011 ↗
L4Cited in: Etiology and Triggering Factors - [172]
Paquette M, Guay SP, Baass A. “Validation of two familial chylomicronemia syndrome clinical diagnosis scores in a cohort of molecularly defined patients.” Journal of clinical lipidology (2026). PMID: 42637648 ↗
L3bCited in: Etiology and Triggering Factors - [173]
Li Y, Wan X, Wang Y et al.. “Combining MRI dual-sequence radiomics and clinical parameters predicts post-hypertriglyceridemic acute pancreatitis diabetes mellitus.” Frontiers in endocrinology (2026). PMID: 42609407 ↗
L3bCited in: Etiology and Triggering Factors - [174]
Zhu K, Lu B, Zhou R et al.. “Lactate Dehydrogenase, Interleukin-6, and 24 h Intra-Abdominal Pressure Exhibit Early Predictive Value in Hypertriglyceridemic Pancreatitis Complicated by Acute Respiratory Distress Syndrome.” Emergency medicine international (2026). PMID: 42688871 ↗
L3bCited in: Etiology and Triggering Factors - [175]
Ahmed K, Ismail A, Elawad A et al.. “Prior bariatric surgery and better short-term outcomes in acute pancreatitis: a multicenter propensity-matched analysis.” Annals of gastroenterology (2026). PMID: 42434159 ↗
L3bCited in: Etiology and Triggering Factors - [176]
Xiang D, Yuan L, Liao S et al.. “A case report of young-onset type 2 diabetes patient with severe metabolic dysregulation carrying an LRP6 variant.” Frontiers in endocrinology (2026). PMID: 42723884 ↗
L4Cited in: Etiology and Triggering Factors - [177]
Liu M, Wu D, Su C. “Insulin is central, plasmapheresis is salvage: clinical spectrum and management of severe hypertriglyceridemia in 21 children with diabetic ketoacidosis.” Frontiers in endocrinology (2026). PMID: 42718762 ↗
L4Cited in: Etiology and Triggering Factors - [178]
Chen X, Zhou L, Huang Y et al.. “Hemoperfusion with Hemodiafiltration Versus Standard Medical Therapy for Severe Acute Pancreatitis: A Retrospective Study.” Digestive diseases and sciences (2026). PMID: 42702672 ↗
L1bCited in: Pathophysiology - [179]
Farrell PR, Lee B, Ahmed F et al.. “TRANCE is a unique marker of chronic pancreatitis in children.” JCI insight (2026). PMID: 42635043 ↗
L2bCited in: Pathophysiology - [180]
Ye HW, Liu F, Gu DJ et al.. “Impact of acute cholangitis severity on the safety of laparoscopic common bile duct exploration with primary closure: a stratified retrospective study.” Surgical endoscopy (2026). PMID: 42680926 ↗
L3bCited in: Pathophysiology - [181]
Vazzana GF, Romano A, Romano C. “Idiopathic Acute Pancreatitis in Paediatric Inflammatory Bowel Disease: Clinical Features and Outcomes in a Retrospective Single-Centre Study.” Journal of paediatrics and child health (2026). PMID: 42625467 ↗
L4Cited in: Pathophysiology - [182]
Kosidło JW, Dorf J, Kamińska J et al.. “Unveiling the multidimensional cytokine landscape in acute pancreatitis.” Frontiers in immunology (2026). PMID: 42643960 ↗
L3bCited in: Pathophysiology - [183]
Obeidat A, Sallam A, Chang C. “Clinical and in-hospital outcomes of alcohol-related pancreatitis in the setting of concomitant alcohol-related hepatitis: A retrospective cohort study.” The American journal of the medical sciences (2026). PMID: 42580663 ↗
L3bCited in: Pathophysiology - [184]
Chen C, Zhao Y, Lin X et al.. “Case Report: A rare case of concurrent diabetic ketoacidosis and severe acute pancreatitis, followed by Guillain-Barré syndrome and Wernicke's encephalopathy.” Frontiers in endocrinology (2026). PMID: 42718484 ↗
L4Cited in: Pathophysiology - [185]
Mititelu A, Grama A, Bența G et al.. “Acute and Recurrent Pancreatitis in Children: Insights into Etiology and Clinical Course from a Retrospective Single-Center Study.” Children (Basel, Switzerland) (2026). PMID: 42650422 ↗
L3bCited in: History and Physical Examination - [186]
Bhattarai S, Baral S, Bhowmick M et al.. “Short-Term Changes in Body Composition and the Development of Sarcopenia Following Acute Pancreatitis: An Observational Study.” Digestive diseases and sciences (2026). PMID: 42223541 ↗
L3bCited in: History and Physical Examination - [187]
Agaoglu Z, Toptas GR, Serbetci H et al.. “Evaluation of Maternal and Fetal Outcomes in Pregnant Women with Acute Pancreatitis: A Five-Year Retrospective Study from a Tertiary Center.” Digestive diseases and sciences (2026). PMID: 42154121 ↗
L3bCited in: History and Physical Examination - [188]
Roberts KM, Thongkhao-On S, Culp S et al.. “Dietary Patterns Following an Episode of Acute Pancreatitis: A Post Hoc Analysis From the PAPPEI Multicenter, Prospective Study.” Pancreas (2026). PMID: 42047302 ↗
L3bCited in: History and Physical Examination - [189]
Chen SC, Liu KW, Huang YN et al.. “Two-Year Biomarker Trends and Kidney/Mortality Outcomes After Semaglutide Versus Phentermine-Topiramate and Naltrexone-Bupropion in People With Obesity and Without Diabetes.” American journal of therapeutics (2026). PMID: 41992281 ↗
L3bCited in: History and Physical Examination - [190]
Chleirigh NN, O'Broin ER, Shet S et al.. “10 year cumulative diagnostic radiation exposure after acute pancreatitis: a retrospective comparison of acute interstitial oedematous and necrotising pancreatitis.” BMC gastroenterology (2026). PMID: 41888675 ↗
L4Cited in: History and Physical Examination - [191]
Calabrese EC, Shehata D, Slater BJ et al.. “SAGES clinical practice guidelines for the management of symptomatic walled-off pancreatic necrosis.” Surgical endoscopy (2026). PMID: 42675307 ↗
L1cCited in: Supportive Care and Complication Management - [192]
Fang Y, Chen X, Cai L et al.. “Comparative efficacy and safety of Xuesaitong injection as adjuvant therapy for acute pancreatitis: a systematic review and meta-analysis.” Frontiers in pharmacology (2026). PMID: 42591735 ↗
L1aCited in: Supportive Care and Complication Management - [193]
Jiang W, Peng J, Wu Q et al.. “Normal saline vs. lactated ringer's for fluid resuscitation in acute pancreatitis: a systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 42180723 ↗
L1aCited in: Supportive Care and Complication Management - [194]
Ding L, Wang Z, Wang Y et al.. “Hypertriglyceridemic pancreatitis subphenotypes and differential responses to low-molecular-weight heparin: analyses from a cohort and a randomized controlled trial.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 42420072 ↗
L1bCited in: Supportive Care and Complication Management - [195]
Wu Y, Gao Y, Fang Z et al.. “Time-dependent microbiology of peripancreatic drainage fluid in severe acute pancreatitis: a prospective real-world observational study using metagenomic sequencing and culture.” Frontiers in medicine (2026). PMID: 42328576 ↗
L2bCited in: Supportive Care and Complication Management - [196]
Chen X, Su L, Zhang D et al.. “Association between peak D-dimer levels within 24 hours of admission and the risk of infected pancreatic necrosis in hyperlipidemic acute pancreatitis: a retrospective analysis.” Frontiers in medicine (2026). PMID: 42712372 ↗
L3bCited in: Supportive Care and Complication Management - [197]
Zuo Q, Cui M, Li J et al.. “Robot-assisted pancreatic necrosectomy for infected pancreatic necrosis secondary to severe acute pancreatitis: a single-center retrospective cohort study.” Journal of robotic surgery (2026). PMID: 42671732 ↗
L3bCited in: Supportive Care and Complication Management - [198]
Ouyang S, Fan Y, Liu F et al.. “Automated CT Volumetry of Peripancreatic Collections for Risk Stratification in Acute Pancreatitis: A Multicenter Retrospective Study.” Academic radiology (2026). PMID: 42567794 ↗
L3bCited in: Supportive Care and Complication Management - [199]
Anandalwar SP, Clark J, Vesselinov R et al.. “Does the risk outweigh the benefit? Clot progression, recanalization & complications of anticoagulation therapy in acute pancreatitis with concomitant splanchnic vein thrombosis.” American journal of surgery (2026). PMID: 42398215 ↗
L3bCited in: Supportive Care and Complication Management - [200]
Zhang H, Chen D, Tian H et al.. “Perioperative nursing management in video-assisted retroperitoneal debridement for severe acute pancreatitis with infected peripancreatic necrosis: a retrospective single-center case series of 41 patients.” Frontiers in surgery (2026). PMID: 42369635 ↗
L4Cited in: Supportive Care and Complication Management - [201]
Zhang JX, Jin HS, Lu SS et al.. “Potential benefit of mirabilite external dressing combined with abdominal drainage in the early stage of severe acute pancreatitis.” BMC gastroenterology (2026). PMID: 42426625 ↗
L2bCited in: Supportive Care and Complication Management - [202]
Hayashi H, Kubo T, Hara T et al.. “Non-keratinizing immature squamous metaplasia in the pancreas mimicking malignancy: a diagnostic pitfall in cytology.” Journal of pathology and translational medicine (2026). PMID: 42452874 ↗
L3bCited in: Supportive Care and Complication Management - [203]
Lan L, Cheng G, He M et al.. “Fluid resuscitation in the early management of acute pancreatitis: a five-year retrospective observational study.” World journal of emergency medicine (2026). PMID: 42199765 ↗
L3bCited in: Supportive Care and Complication Management - [204]
Grover AS, Reiss DE, Templeton K et al.. “Endoscopic ultrasound-guided drainage of pancreatic fluid collections is safe to perform in children: A comparison of two endoscopic approaches.” Journal of pediatric gastroenterology and nutrition (2026). PMID: 42626823 ↗
L4Cited in: Supportive Care and Complication Management - [205]
Li M, Fu Y, Chen Y et al.. “Case Report: Early documented infected pancreatic necrosis due to carbapenem-resistant Acinetobacter baumannii and concurrent Enterococcus faecium bacteremia: a salvage regimen with sulbactam-durlobactam and tigecycline.” Frontiers in medicine (2026). PMID: 42440864 ↗
L4Cited in: Supportive Care and Complication Management - [206]
Jacq E, Maire F, Cucherousset J et al.. “From Cutaneous Necrosis to Septic Shock: An ICU Case of Pancreatico portal Fistula Complicating Necrotizing Acute Pancreatitis.” Critical care explorations (2026). PMID: 42390290 ↗
L4Cited in: Supportive Care and Complication Management